| 445 |
Drug-Induced Liver Injury: Interaction Between Drug Properties and Host Factors |
2015 |
| 411 |
FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury |
2011 |
| 354 |
High Lipophilicity and High Daily Dose of Oral Medications are Associated with Significant Risk for Drug-Induced Liver Injury |
2013 |
| 284 |
DILIrank: The Largest Reference Drug List Ranked by the Risk for Developing Drug-Induced Liver Injury in Humans |
2016 |
| 174 |
A Decade of Toxicogenomic Research and Its Contribution to Toxicological Science |
2012 |
| 148 |
Predicting Hepatotoxicity Using ToxCast In Vitro Bioactivity and Chemical Structure |
2015 |
| 147 |
Toward Predictive Models for Drug-Induced Liver Injury in Humans: Are We There Yet? |
2014 |
| 111 |
High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes are Two Important Predictors of Drug-induced Liver Injury |
2014 |
| 107 |
Biomarkers for Drug-Induced Liver Injury |
2010 |
| 107 |
Drug-Induced Liver Toxicity |
2018 |
| 101 |
Quantitative Structure-Activity Relationship Models for Predicting Drug-Induced Liver Injury Based on FDA-Approved Drug Labeling Annotation and Using a Large Collection of Drugs |
2013 |
| 95 |
Liver Toxicity Knowledge Base (LTKB) – A Systems Approach to a Complex Endpoint |
2013 |
| 95 |
Translating Clinical Findings into Knowledge in Drug Safety Evaluation—Drug Induced Liver Injury Prediction System (DILIps) |
2011 |
| 91 |
A Model to Predict Severity of Drug-Induced Liver Injury in Humans |
2016 |
